ROCKVILLE, Md., Feb. 11 /PRNewswire/ -- OriGene Technologies, Inc. ("OriGene") today announced it has raised an additional $6.5 million in a private equity financing. With this financing, OriGene completed the acquisition of the assets of privately held Shenzhen P&A Biotech, a manufacturer and provider of monoclonal antibodies (mAb) to the research community. With this acquisition OriGene completes the establishment of its technology center to develop genome-wide monoclonal antibodies to all human proteins.
Over the last ten years OriGene has developed the capacity to produce thousands of human full-length proteins from human cells. These human cell produced human proteins are ideal antigens for high throughput monoclonal antibody production. During the last two years, OriGene also has developed a genome wide collection of antigen standards and over 100,000 tissue samples that are ideal tools for high quality antibody validation. With OriGene's China monoclonal antibody production capacity and these unique genome-wide resources OriGene believes it can produce several thousand high quality monoclonal antibodies per year.
This genome-wide mAb production capacity is available to all commercial and academic partners with a long-term goal to providing high quality monoclonal antibodies for every single human gene.
OriGene Technologies, Inc. is a gene centric life sciences tool company dedicated to support academic, pharmaceutical and biotech companies for research and drug discovery. Our flagship products are the world's largest cDNA and shRNA clone collections. Other key products include over 100,000 highly validated human tissues through its wholly owned subsidiary Cytomyx LLC., and its tissue derivative products tissue qPCR arrays for biomarker discovery and validation. OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards
|SOURCE OriGene Technologies Inc.|
Copyright©2009 PR Newswire.
All rights reserved